tbuckley/cabot-search huggingface dataset:
The Association of Hidradenitis Suppurativa and Psychiatric Disease: A Systematic Review and Meta-analysis
Authors: Caroline L Folkmann, Emilie H Pinborg, Mette Iversen, Amalie T M Rønnstad, Nielsen Holgersen, Mia-Louise Nielsen, Alexander Egeberg, Jacob P Thyssen, Simon F Thomsen, Maria O Christensen
Journal: British Journal of Dermatology (2025)

Abstract Background Hidradenitis suppurativa (HS) has been associated with increased risk of psychiatric disease (PD) compared to the general population. However, to our knowledge, no recent comprehensive examination of the prevalence and association between HS and PD has been made. Objectives To investigate the association between HS and PD. Methods A systematic review and meta-analysis was performed using standard methodologies and was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The medical databases PubMed, EMBASE, PsychINFO, Cochrane, Web of Science, and the Directory of Open Access Journals were searched. Studies were included if addressing HS and any PD. Study quality was assessed through Newcastle-Ottawa Scale (NOS). Certainty of evidence was assessed using the GRADE approach. Results A total of 83 studies were included in the narrative analysis of which 76 were included in the quantitative analysis. This study found that patients with HS had higher risk of depression, pooled prevalence 20.9% vs. 8.35%, OR 2.06 [1.75-2.41], p&amp;lt;0.0001; anxiety, 19.3% vs. 8.14%, OR 1.91 [1.64-2.22], p&amp;lt;0.0001; bipolar disorder, 1.04% vs. 0.06%, OR 3.68 [1.11-12.2], p=0.0332; schizophrenia, 2.68% vs. 1.23%, OR 2.00 [1.21-3.30], p=0.007; substance use disorder 6.02% vs. 3.12%, OR 3.58 [2.01-6.37], p&amp;lt;0.0001; alcohol abuse, 3.97% vs. 1.84%, OR 1.88 [0.98-3.58], p=0.0571, and completed suicide 0.67% vs. 0.44%, OR 1.56 [1.14-2.14], p=0.0054 when compared to general population. PD was more prevalent in females with HS (28%) compared to males (21%). Depression increased with increasing Hurley Stage (I=19.5%, II=20.9%, and II=35.3%, p&amp;lt;0.0001). North American studies had higher pooled prevalence of PD compared to European studies (35.4% vs. 21.2%). Adults had higher pooled prevalence of depression compared to children (19.1% vs. 9.51%). Half of included studies were assessed as high quality (NOS≥7). Conclusions This study found a significantly higher risk of several PDs in patients with HS compared to the general population. Our findings reflect a need to raise awareness of psychiatric illnesses in patients with HS to improve patients’ quality of life.
Molecular signatures define <i>BAP1</i>-altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genes
Authors: Philipp Sievers, Sonali Arora, Thomas Hielscher, Dilan Savran, Daniel Schrimpf, Rouzbeh Banan, David Vonhören, Stefan Pusch, Martin Sill, Romain Appay, Hans-Georg Wirsching, Tibor Hortobagyi, Hildegard Dohmen, Till Acker, Patricia Kohlhof‑Meinecke, Leonille Schweizer, Annika K Wefers, Patrick N Harter, Christian Hartmann, Rudi Beschorner, Jens Schittenhelm, Felix Behling, Ghazaleh Tabatabai, Christian Mawrin, Matija Snuderl, Sybren L N Maas, Pieter Wesseling, Sebastian Brandner, Andrey Korshunov, Miriam Ratliff, Sandro M Krieg, Wolfgang Wick, David T W Jones, Stefan M Pfister, Eric C Holland, Andreas von Deimling, Frank Szulzewsky, Felix Sahm
Journal: Neuro-Oncology (2025)

Meningiomas are the most common primary intracranial neoplasms, with highly variable patient outcomes. While most meningiomas are benign, a significant subset recurs postoperatively, presenting substantial treatment challenges. BAP1 gene inactivation has been suggested as a marker for aggressive meningiomas, although its precise molecular and clinical roles remain poorly understood. To comprehensively investigate BAP1-altered meningiomas, we used six meningiomas with known BAP1 alterations as a discovery set. Genome-wide DNA methylation profiling of these samples, along 11,151 reference meningiomas, identified a distinct molecular cluster (n = 42) using unsupervised visualization approaches. These tumors were further characterized by DNA/RNA sequencing, histopathological examination, and a retrospective review of clinical data, compared to reference meningioma cohorts, providing a thorough characterization of this rare tumor subtype. Our integrative analysis revealed BAP1-altered meningiomas as a distinct CNS tumor subtype, characterized by recurrent loss of chromosome 3p21 and driven by various BAP1-inactivating alterations. Although rhabdoid morphology is present in some cases, it is not exclusive and should not be used as a grading criterion. Progression-free survival analysis showed a median of 21 months (95% CI: 12-NA), with a 2-year overall survival rate of 79% (95% CI: 60%-100%), highlighting the aggressive nature of these tumors. Gene expression profiling revealed upregulation of PRC target genes, dysregulated Polycomb signaling, and elevated expression in several cellular and growth factor pathways. BAP1-altered meningiomas represent a distinct and aggressive CNS tumor subtype associated with PRC dysregulation and recurrent 3p chromosome loss. These findings support the designation "meningioma, BAP1-altered."
Light‐Activatable Hyaluronic Acid‐Derivatives Releasing Nitric Oxide and Their Delivery in the Skin
Authors: Giuseppe Longobardi, Cristina Parisi, Federica Sodano, Ovidio Catanzano, Anna Di Porzio, Antonio Randazzo, Salvatore Sortino, Fabiana Quaglia
Journal: Advanced Healthcare Materials (2025)

Hyaluronic acid (HA), renowned for its hydrating properties, penetrates deeper into the skin at a very low molecular weight, promoting cellular repair and reducing inflammation. Nitric oxide (NO), a gaseous mediator with a very relevant role in many physiological and pathophysiological processes, is expected to complement the functions of HA in the skin through its vasodilatory, anti-inflammatory, and regenerative properties. Herein, a novel class of HA derivatives functionalized with NO photodonors (NOPD) for light-activated therapeutic applications is introduced. The HA derivatives HA-NOPD1 and HA-NOPD2 demonstrated NO release under blue light activation. Biological assays on HaCaT keratinocytes revealed enhanced proliferation and migration under light stimuli, underscoring the therapeutic potential of HA-NOPD1. The derivatives are formulated into microemulsions (MEs) to allow their skin transport. MEs loaded with the photoresponsive derivatives are stable in the dark and provide effective NO photorelease with higher quantum yields than the free compounds. Skin permeation studies using porcine and artificial membranes confirmed that HA-NOPD2 distributed in all the skin layers, reaching the dermis and releasing NO in situ.
Impact of Islet Transplantation on Diabetes Complications and Mortality in Patients Living With Type 1 Diabetes
Authors: Quentin Perrier, Clément Jambon-Barbara, Laurence Kessler, Orianne Villard, Fanny Buron, Bruno Guerci, Sophie Borot, Matthieu Roustit, Ekaterine Berishvilli, Luc Rakotoarisoa, Marie-Christine Vantyghem, Emmanuel Morelon, Eric Renard, Camille Besch, Thierry Berney, Pierre-Yves Benhamou, Sandrine Lablanche, Bénédicte Janbon, Johan Noble, Thomas Jouve, Paolo Malvezzi, Julia Sabatier, Christophe Broca, Sabrina Granziera, Matthieu Heim, Michel Greget, Camille Besch, François Faitot, Ammanuel Morelon, Olivier Thaunat, Lionel Badet, Charles Thivolet, Thierry Berney, Cristine Widmer, Andrea Peloso, Charles-Henri Wassmer, Berishvili Ekaterine, Fanny Lebreton, Géraldine Parnaud, Nadine Pernin, Domenico Bosco, Igor Tauveron, Laure Esposito, Vincent Melki, Pierre Cattan, Marie Noelle Peraldi, Mathieu Armanet, Antoin Durrbach, Luc Frimat, Bruno Guerci
Journal: Diabetes Care (2025)

This study aimed to evaluate the impact of islet transplantation (IT) on diabetes complications, death, and cancer incidence. This retrospective, multicenter, cohort study included patients from three IT clinical trials (intervention group) and from the French health insurance claims database Système National des Données de Santé (SNDS) (control group). Two cohorts of IT recipients were analyzed: IT recipients after kidney transplantation (IAK) and IT recipients alone (ITA). They were matched with patients living with type 1 diabetes (T1D) from the SNDS using a propensity score. The primary outcome was a composite criterion including death, dialysis, amputation, nonfatal stroke, nonfatal myocardial infarction, and transient ischemic attack. The secondary outcome was cancer. Hazard ratio (HRs) and P values were obtained using Cox proportional hazards analysis and log-rank test, respectively. The study included 61 ITA recipients matched to 610 T1D control patients and 45 IAK recipients matched to 45 T1D control patients over a median follow-up period >10 years. Compared with T1D control patients, ITA and IAK recipients had a lower composite outcome risk (HR 0.39 [95% CI 0.21-0.71; P = 0.002] and 0.52 [0.30-0.88; P = 0.014], respectively) that seemed driven by reduced mortality (0.22 [0.09-0.54]; P < 0.001) for ITA and reduced dialysis (0.19 [0.07-0.50]; P < 0.001) for IAK. Both groups showed no significant changes in cancer risk. This study suggests long-term benefits of IT on diabetes-related outcomes. Furthermore, despite the use of immunosuppressive drugs following IT, we observed no significant increase in the risk of cancer. Altogether, these findings highlight a favorable risk-benefit ratio of IT in treating patients with unstable T1D.
Energy Restriction, Weight Loss, Glycemia, and Breastfeeding Outcomes in Gestational Diabetes: A DiGest Trial Secondary Analysis
Authors: Sarah Dib, Laura C. Kusinski, Danielle L. Jones, Nooria Atta, Suzanne Smith, Emanuella De Lucia Rolfe, Helen R. Murphy, Roy Taylor, Claire L. Meek
Journal: Diabetes Care (2025)

We aimed to assess whether energy restriction, weight loss, or maternal glycemia in late pregnancy were associated with breastfeeding outcomes. This is a secondary analysis of the Dietary Intervention in Gestational Diabetes (DiGest) randomized controlled trial, which included 425 participants with gestational diabetes who were randomly assigned to receive a standard-energy (2,000 kcal/day) or reduced-energy (1,200 kcal/day) diet box from 29 weeks until delivery, with masked continuous glucose monitoring. Breastfeeding intentions and outcomes were documented (n = 304 of 425) and analyzed using regression models. Energy restriction in late pregnancy did not affect breastfeeding outcomes. Achieving ≥90% time in range (3.5-6.7 mmol/L; 63-120 mg/dL) with a low glycemic variability (coefficient of variation and SD), but not weight loss, were associated with any breastfeeding at 3 months postnatally. Improved late pregnancy glycemia and decreased glucose variability, but not weight loss or energy restriction, were associated with breastfeeding after gestational diabetes.
Clinical presentation, diagnostics, and outcomes of infants with congenital and postnatal tuberculosis: a multicentre cohort study of the Paediatric Tuberculosis Network European Trials Group (ptbnet)
Authors: Florian Götzinger, Alejandra Alonso Caprile, Antoni Noguera-Julian, Andrea Lo Vecchio, Fernando Baquero-Artigao, Teresa Del Rosal, Folke Brinkmann, Françoise Mouchet, Svetlana Velizarova, Karsten Kötz, Nicole Ritz, Danilo Buonsenso, Rinn Song, Robindra Basu Roy, Tea Nieminen, Cornelius Rau, Vira Chechenieva, Steven Welch, Petra Kaiser-Labusch, Marieke Emonts, Charlotte Buxbaum, Daniel Blázquez-Gamero, Alasdair Bamford, Marc Tebruegge, Nuria Martinez-Alier
Journal: The Lancet Regional Health - Europe (2025)
Overcoming barriers in the use of artificial intelligence in point of care ultrasound
Authors: Roberto Vega, Masood Dehghan, Arun Nagdev, Brian Buchanan, Jeevesh Kapur, Jacob L Jaremko, Dornoosh Zonoobi
Journal: npj Digital Medicine (2025)

Point-of-care ultrasound is a portable, low-cost imaging technology focused on answering specific clinical questions in real time. Artificial intelligence amplifies its capabilities by aiding clinicians in the acquisition and interpretation of the images; however, there are growing concerns on its effectiveness and trustworthiness. Here, we address key issues such as population bias, explainability and training of artificial intelligence in this field and propose approaches to ensure clinical effectiveness.
Transforming treatment paradigms: Focus on personalized medicine for high‐grade serous ovarian cancer
Authors: Pawel Kordowitzki, Britta Lange, Kevin M. Elias, Marcia C. Haigis, Sylvia Mechsner, Ioana Elena Braicu, Jalid Sehouli
Journal: CA A Cancer Journal for Clinicians (2025)

Abstract High‐grade serous ovarian cancer (HGSOC) is the most common and aggressive subtype of ovarian cancer, accounting for approximately 70% of all ovarian cancer cases and contributing significantly to the high mortality rates associated with this disease. Because of the asymptomatic nature of early stage disease, most patients are diagnosed at advanced stages when the cancer has already spread into the abdominal cavity, requiring complex and intensive surgical and chemotherapeutic interventions followed by maintenance therapies. Although a minority of cases are associated with well defined genetic syndromes, specific risk factors and a clear etiology in many cases remain elusive. HGSOC tumors are characterized by a high frequency of somatic gene copy number alterations, often associated with defects in homologous recombination repair of DNA. All attempts to introduce an effective screening for HGSOC to date have been unsuccessful. This review elucidates the complexities surrounding HGSOC and encompasses its etiology, epidemiology, classification, pathogenesis, and the current array of treatment strategies. Understanding molecular underpinnings is crucial for the development of targeted therapies and personalized multimodal treatment approaches in centralized therapeutic structures. This review also examines the importance of the tumor microenvironment. In addition, the authors' objective is to underscore the critical importance of placing the patient's perspective and diversity at the forefront of therapeutic strategies, thereby fostering a genuinely participatory decision‐making process and ultimately improving patient quality of life.
Precisely edited gut microbiota by tungsten-doped Prussian blue nanoparticles for the treatment of inflammatory bowel disease
Authors: Lingpeng Luo, Qingyun Liu, Yushi Zhang, Xuya Yu, Ling Wang, Weiting Sun, Tingxuan Li, Bin Xu, Kai Zhang, Yongkang Yu, Chunhui Cui, Chen Li, Lin Mei
Journal: Journal of Controlled Release (2025)
Transformable albumin-based nanocapsules selectively amplify tumor starvation and disulfidptosis through metabolic deception
Authors: Yang Li, Yishi Lu, Wei Lu, Nan Zhong, Na Li, Ziqing Xu, Jie Zhang, Hanyao Sun, Feiyun Wu, Zhaogang Teng, Yuxia Tang, Shouju Wang
Journal: Journal of Controlled Release (2025)
Hypoxia-responsive oncolytic conjugate triggers type-II immunogenic cell death for enhanced photodynamic immunotherapy
Authors: Maomao Ren, Xin Sun, Jiayi Lin, Yajie Kan, Shengxin Lu, Xiaokun Zhang, Rui Liang, Bei Wang, Hongzhuan Chen, Ye Wu, Xin Luan
Journal: Journal of Controlled Release (2025)
The Barcelona baseline risk score to predict long-term prognosis after a first demyelinating event: a prospective observational study
Authors: Carmen Tur, Pere Carbonell-Mirabent, Susana Otero-Romero, Álvaro Cobo-Calvo, María Jesús Arévalo, Helena Ariño, Georgina Arrambide, Cristina Auger, René Carvajal, Joaquín Castilló, Manuel Comabella, Ingrid Galán, Luciana Midaglia, Carlos Nos, Agustín Pappolla, Deborah Pareto, Jordi Río, Breogán Rodríguez-Acevedo, Estibaliz Saez de Gordoa, Ángela Vidal-Jordana, Ana Zabalza, Jaume Sastre-Garriga, Àlex Rovira, Xavier Montalban, Mar Tintoré
Journal: The Lancet Regional Health - Europe (2025)
Surveillance with [18F]FDG PET/CT of stage I-III lung cancer patients after completion of curative treatment (SUPE_R): a randomized controlled trial
Authors: Kasper Foged Guldbrandsen, Martin Bloch, Kristin Skougaard, Lise Barlebo Ahlborn, Erik Jakobsen, Anette Højsgaard, Rene Horsleben Petersen, Lars Borgbjerg Møller, Morten Dahl, Boe Sandahl Sorensen, Malene Støchkel Frank, Jeanette Haar Ehlers, Martin Krakauer, Peter Michael Gørtz, Elisabeth Albrecht-Beste, Julie Marie Grüner, Zaigham Saghir, Joan Fledelius, Anne Lerberg Nielsen, Paw Christian Holdgaard, Søren Steen Nielsen, Mette Pøhl, Svetlana Borissova, Lotte Holm Land, Charlotte Kristiansen, Tine McCulloch, Lise Saksø Mortensen, Hanne Marie Nellemann, Malene Søby Christophersen, Ole Hilberg, Thor Lind Rasmussen, Signe Høyer Simonsen Schwaner, Christian B Laursen, Uffe Bodtger, Liza Sopina, Markus Nowak Lonsdale, Christian Niels Meyer, Oke Gerke, Jann Mortensen, Torben Riis Rasmussen, Barbara Malene Fischer
Journal: Journal of Thoracic Oncology (2025)
Design, synthesis and biological evaluation of a novel class of indazole-containing compounds with potent anti-influenza activities targeting the PA-PB1 interface
Authors: Yun-Sang Tang, Chao Zhang, Jing Xu, Haibo Zhang, Zhe Jin, Mengjie Xiao, Nuermila Yiliyaer, Er-Fang Huang, Xin Zhao, Chun Hu, Pang-Chui Shaw
Journal: Acta Pharmaceutica Sinica B (2025)
High-dose versus standard dose twice-daily thoracic radiotherapy in limited stage small-cell lung cancer: final survival data, long-term toxicity and relapse patterns in a randomised, open-label, phase II trial
Authors: Bjørn Henning Grønberg, Kristin Toftaker Killingberg, Øystein Fløtten, Maria Moksnes Bjaanæs, Odd Terje Brustugun, Tesfaye Madebo, Seppo Wang Langer, Signe Lenora Risumlund, Tine Schytte, Nina Helbekkmo, Kirill Neumann, Øyvind Yksnøy, Jens Engleson, Sverre Fluge, Thor Naustdal, Liv Ellen Giske, Jan Nyman, Georgios Tsakonas, Tarje Onsøien Halvorsen
Journal: Journal of Thoracic Oncology (2025)

Chemoradiotherapy is standard treatment for limited stage (LS) small-cell lung cancer (SCLC). A majority of patients relapse and there is a need for better treatment. We investigated whether twice-daily thoracic radiotherapy (TRT) of 60 Gy/40 fractions improve survival compared with the established schedule of 45 Gy/30 fractions. Here we report final survival data and long-term toxicity. Randomised, open-label, phase II trial. Eligible patients had PS 0-2, were ≥18 years, underwent FDG-PET/CT and brain MRI for staging and were randomised 1:1 to TRT of 60 or 45 Gy. Patients were to receive four courses of platinum/etoposide chemotherapy and responders were offered prophylactic cranial irradiation. 170 patients were randomized (60 Gy: n=89, 45 Gy: n=81). Median age was 65, 31% ≥70 years, 57% women, 89% had PS 0-1, 83% stage III disease, median planning target volume was 305 cm3, and 67% were treated with three-dimensional conformal radiotherapy (3D CRT). Median OS in the 60 Gy group was significantly longer (43.5 vs. 22.5 months, HR 0.68, 95% CI 0.48-0.98, p=0.037). The 60 Gy group did not experience more acute grade 3-4 esophagitis (60 Gy: 21%, 45 Gy: 18%, p=0.83) or pneumonitis (60 Gy: 3%, 45 Gy: 0%, p=0.39). Two patients, both in the 60 Gy group, developed oesophageal strictures, while eleven patients (60 Gy: n=5, 45 Gy: n=6) developed severe long-term eating and swallowing dysfunction. Twice-daily TRT of 60 Gy/40 fractions was well tolerated and prolonged survival compared with 45 Gy/30 fractions in LS SCLC patients.
The importance of biome in shaping urban biodiversity
Authors: Eleanor S Diamant, Krista N Oswald, Adewale G Awoyemi, Kevin J Gaston, Ian MacGregor-Fors, Oded Berger-Tal, Uri Roll
Journal: Trends in Ecology & Evolution (2025)

Humanity is urbanizing, with vast implications on natural systems. To date, most research on urban biodiversity has centered on temperate biomes. Conversely, drylands, collectively the largest terrestrial global biome, remain understudied. Here, we synthesize key mechanistic differences of urbanization's impacts on biodiversity across these biomes. Irrigation shapes dryland urban ecology, and can lead to greener, sometimes more biodiverse, landscapes than local wildlands. These green urban patches in drylands often have a different species composition, including many non-native and human-commensal species. Socioeconomic factors - locally and globally - can mediate how biomes shape urban biodiversity patterns through the effects of irrigation, greening, and invasive species. We advocate for more research in low-income dryland cities, and for implementing biome-specific, scientifically grounded management and policies.
The Chronobiology of Hormone Administration: “Doctor, what time should I take my medication?”
Authors: Elena Colonnello, Andrea Graziani, Rebecca Rossetti, Giacomo Voltan, Davide Masi, Carla Lubrano, Stefania Mariani, Mikiko Watanabe, Andrea Marcello Isidori, Alberto Ferlin, Lucio Gnessi
Journal: Endocrine Reviews (2025)

Abstract Pharmacotherapy involving hormones and hormone-derived molecules has various potential treatment targets. This includes addressing (partial) hormonal deficiencies, pursuing osteoanabolic effects, providing contraceptive options, or supporting gender-affirming transitions. In chronotherapy, the timing of the administration of active ingredients and different pharmaceutical forms is leveraged to maximize therapeutic efficacy while minimizing adverse effects, based on the principle that it is optimal for drugs to be administered according to the body’s circadian rhythms. Just as a drummer sets the pace and keeps the rhythm steady for the entire band, the physician, through the application of chronotherapy, ensures the treatment regimen is harmonized with the body's internal clock. However, while this is a consolidated aspect for several endocrine treatments, for others, it represents a novelty. The new advancements in the treatment of osteoporosis, with the latest Parathyroid Hormone-Related Protein analogue abaloparatide, or in congenital adrenal hyperplasia with the new long-lasting hydrocortisone formulation, are notable examples. We herein summarized the state-of-the-art regarding the hormonal circadian rhythm to discuss in depth the evidence available regarding the correct timing of commonly administered hormonal therapies in adult patients. By offering clear indications this manuscript delves into the importance of harmonizing hormonal therapy with circadian rhythms through chronotherapy, exploring its potential to enhance therapeutic outcomes while minimizing adverse effects.
Delivery mode, birth order, and sex impact neonatal microbial colonization
Authors: Katherine M. Kennedy, Andreas Plagemann, Julia Sommer, Marie Hofmann, Wolfgang Henrich, Michael G. Surette, Thorsten Braun, Deborah M. Sloboda
Journal: Gut Microbes (2025)

The initial microbial colonization of the infant gut during birth plays a critical role in shaping both immediate and long-term health outcomes. While mode of delivery is a known determinant of this colonization process, the potential impacts of infant sex and birth order remain underexplored. This study investigates the influence of delivery mode, infant sex, and birth order (maternal parity) on the microbial communities in first-pass meconium samples from neonates, using 16S rRNA gene sequencing. We found that delivery mode impacted the presence of detectable microbial communities. Specifically, only 17% of samples from neonates delivered by elective Cesarean section showed any microbial presence, compared to approximately two-thirds of samples from neonates exposed to maternal vaginal microbes (emergency C-section or vaginal delivery). Among vaginally delivered neonates without antibiotic exposure, birth order was associated with taxonomic shifts. Neonates born to primiparous mothers had a lower abundance of Bifidobacterium, a keystone species in the infant gut microbiome. Unexpectedly, the gut microbiota differed by infant sex, with males having lower alpha diversity and shifts in microbial community composition (PERMANOVA p = 0.008), characterized by elevated levels of Enterobacteriales, which was both less prevalent and less abundant in female neonates. These findings highlight the intricate interplay between delivery mode, infant sex, and birth order in shaping the early gut microbiome.